Newer anticonvulsants: Lamotrigine, topiramate and gabapentin

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 94, Issue 8, 2012, Pages 599-606

  Holmes, Lewis B ^a,c   Hernandez Diaz, Sonia ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENTERMINE PLUS TOPIRAMATE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ANTICONVULSANT THERAPY; ARTICLE; CESAREAN SECTION; CHILD DEVELOPMENT; CLEFT FACE; CLEFT PALATE; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONGENITAL MALFORMATION; DELIVERY; DEVELOPMENTAL DISORDER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; EPILEPSY; FETUS RISK; GESTATIONAL AGE; GROWTH RETARDATION; HUMAN; HYDRONEPHROSIS; INTELLIGENCE QUOTIENT; LEARNING; LEARNING DISORDER; LOW BIRTH WEIGHT; MIDFACE HYPOPLASIA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; NONHUMAN; PREECLAMPSIA; PREGNANCY; PREMATURE FETUS MEMBRANE RUPTURE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REGISTER; SMALL FOR DATE INFANT; SYSTEMATIC REVIEW; TERATOGENESIS; TERATOGENICITY; TETHERED CORD SYNDROME; THERAPY;

ABNORMALITIES, DRUG-INDUCED; ADULT; AMINES; ANTICONVULSANTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CLEFT PALATE; COGNITION; COHORT STUDIES; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; GESTATIONAL AGE; HUMANS; INFANT; INFANT, NEWBORN; LEARNING; MATERNAL EXPOSURE; PREGNANCY; REGISTRIES; RISK; TRIAZINES;

EID: 84865077053     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23028     Document Type: Article

References (51)

1. Bockbrader HN, Wesche D, Miller R, et al. 2010. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 49: 661-669.
2. Borthen I, Eide MG, Daltveit AK, Gilhus NE. 2011. Obstetric outcome in women with epilepsy: a hospital-based, retrospective study. BJOG 118: 956-965.
3. Cummings, C. Stewart M, Stevenson M, et al., 2011. Neurodevelopement of children exposed in utero tolomotrigine, sodium valproate and carbamazepine Arc Dis Child 96:643-647.
4. Cunnington M, Tennis P; International Lamotrigine Pregnancy Registry Scientific Advisory Committee. 2005. Lamotrigine and the risk of malformations in pregnancy. Neurology 64: 955-960.
5. Garvey WT, Ryan DH, Look M, et al. 2012. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 95: 297-308.
6. Glauser TA. 1999. Topiramate. Epilepsia 40 Suppl 5: S71-S80.
7. Guttuso TJr, Robinson LK, Amankwah KS. 2010. Gabapentin use in hyperemesis gravidarum: a pilot study. Early Hum Dev 86: 65-66.
8. Harden CL, Hopp J, Ting TY, et al. 2009. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 73: 126-132.
9. Hernandez-Diaz S, Mittendorf R, Holmes LB. 2010. Comparative safety of topiramate during pregnancy. Birth Defects Res A Clin Mol Teratol 88: 408.
10. Hernandez-Diaz S, Smith CR, Shen A, et al. 2012. Comparative safety of anticonvulsants during pregnancy. Neurology 18:1692-1699.
11. Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. 2010. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother 10: 943-959.
12. Holmes LB, Baldwin EJ, Smith CR, et al. 2008. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 70(22 Pt 2 ): 2152-2158.
13. Holmes LB, Coull BA, Dorfman J, Rosenberger PB. 2005. The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. J Pediatr 146: 118-122.
14. Holmes LB, Harvey EA, Coull BA, et al. 2001. The teratogenicity of anticonvulsant drugs. N Engl J Med 344: 1132-1138.
15. Holmes LB, Mittendorf R, Shen A, et al. 2011. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 68: 1275-1281.
16. Honein MA, Paulozzi LJ, Cragan JD, Correa A. 1999. Evaluation of selected characteristics of pregnancy drug registries. Teratology 60: 356-364.
17. Hunt S, Russell A, Smithson WH, et al. 2008. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 71: 272-276.
18. Hunt SJ, Craig JJ, Morrow JI. 2009. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 72: 1108; author reply 1108-1109.
19. Johannessen Landmark C, Patsalos PN. 2010. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 10: 119-140.
20. Johannessen SI, Tomson T. 2006. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 45: 1061-1075.
21. Karceski S, Morrell MJ, Carpenter D. 2005. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 7 Suppl 1: S1-S64; quiz S65-67.
22. Kelly VM, Nelson LM, Chakravarty EF. 2009. Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology 73: 1831-1836.
23. Landmark CJ, Fossmark H, Larsson PG, et al. 2011. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 95: 51-59.
24. Leach MJ, Marden CM, Miller AA. 1986. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 27: 490-497.
25. Margulis AV, Werler MM, Mitchell AA, Hernandez-Diaz S. 2011. Use of topiramate in pregnancy and the risks of oral clefts. Pharmacoepidemiol Drug Saf Supplement 20: S11 (abstract).
26. Mawer G, Clayton-Smith J, Coyle H, Kini U. 2002. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 11: 512-518.
27. Meador KJ, Baker GA, Browning N, et al. 2009. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360: 1597-1605.
28. Meador KJ, Baker GA, Browning N, et al. 2011. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 134(Pt 2): 396-404.
29. Mølgaard-Nielsen D, Hviid A. 2011. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 305: 1996-2002.
30. Montouris G. 2003. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav 4: 310-317.
31. Moore SJ, Turnpenny P, Quinn A, et al. 2000. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 37: 489-497.
32. Morrow J, Russell A, Guthrie E, et al. 2006. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77: 193-198.
33. Nadelbaum C, Anderson VA, Vadja F, et al. 2011. Language skills of school-aged Children prenatally exposed to antiepileptic drugs. Neurology 76:719-726.
34. Nelson K, Holmes LB. 1989. Malformations due to presumed spontaneous mutations in newborn infants. N Engl J Med 320: 19-23.
35. Ohman I, Beck O, Vitols S, Tomson T. 2008. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 49: 1075-1080.
36. Ornoy A, Cohen E. 1996. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 75: 517-520.
37. Ornoy A, Zvi N, Arnon J, et al. 2008. The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod Toxicol 25: 388-389.
38. Orup HIJr, Holmes LB, Keith DA, Coull BA. 2003. Craniofacial skeletal deviations following in utero exposure to the anticonvulsant phenytoin: monotherapy and polytherapy. Orthod Craniofac Res 6: 2-19.
39. Pennell PB. 2003. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 61(6 Suppl 2 ): S35-S42.
40. Petrere JA, Andreson JA. 1994. Developmental toxicity studies in mice, rats and rabbits with the anticonvulsant gabapentin. Fund Appl Toxicology 23:585-589.
41. Prakash, Prabha LV, Rai R, et al., 2008. Teratogenic effects of the anticonvulsant gabapentin in mice. Sing Med J 49:47-53.
42. Reimers A, Helde G, Bråthen G, Brodtkorb E. 2011. Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. Epilepsy Res [Epub ahead of print].
43. Rothman KJ, Boice JDJr. 1979. Epidemiologic analysis with a programmable calculator. Bethesda, Maryland: U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health. NIH Publication No. 79-1649.
44. Samrén EB, van Duijn CM, Christiaens GC, et al. 1999. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 46: 739-746.
45. Tomson T, Battino D. 2007. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet 46: 209-219.
46. Tomson T, Battino D, Craig J, et al. 2010. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia 51: 909-915.
47. Tomson T, Battino D, Bonizzoni E, et al. 2011. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10: 609-617.
48. Vajda FJE, Hitchcock A, Graham J, et al. 2007. The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynecol 47: 468-474.
49. Vajda FJ, Graham J, Rosen A, et al. 2012. Teratogenicity of the newer antiepileptic drugs-the Australian experience. J Clin Neurosci 19: 57-59.
50. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. 2009. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 50: 2130-2139.
51. Wide K, Winbladh B, Källén B. 2004. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 93: 174-176.